Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
19,579 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT03629171 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03643510 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03969706 | Abemaciclib in Patients With Oligodendroglioma | completed | Phase 2 | 10 | Stephen Bagley, MD, MSCEOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | suspended | Phase 1 / Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | recruiting | Phase 1 / Phase 2 | 75 | Turning Point Therapeutics, Inc.INDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT04123379 | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 2 | 48 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04133636 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma(CARTITUDE-2) | active not recruiting | Phase 2 | 208 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT04253964 | Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | recruiting | Phase 2 | 105 | Wake Forest University Health SciencesOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04634552 | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma(MonumenTAL-1) | recruiting | Phase 2 | 510 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT04640623 | A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy(SunRISe-1) | active not recruiting | Phase 2 | 220 | Janssen Research & Development, LLCINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04811560 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)(cAMeLot-1) | recruiting | Phase 1 / Phase 2 | 420 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04858334 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | recruiting | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | active not recruiting | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04925479 | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04989803 | Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma(PALISADES-1) | recruiting | Phase 1 / Phase 2 | 247 | Kite, A Gilead CompanyINDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | recruiting | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | recruiting | Phase 2 / Phase 3 | 290 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05183204 | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | completed | Phase 2 | 24 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05287113 | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 176 | Incyte Biosciences International SàrlINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 235 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT05327010 | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | active not recruiting | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05379595 | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer(OrigAMI-1) | recruiting | Phase 1 / Phase 2 | 225 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT05474846 | Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer | active not recruiting | Phase 2 / Phase 3 | 169 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05488314 | A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer(METalmark) | active not recruiting | Phase 1 / Phase 2 | 57 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT05498155 | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer(OlympiaN) | completed | Phase 2 | 50 | AstraZenecaINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer(COMPANION-003) | completed | Phase 2 | 49 | Compass TherapeuticsINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05528133 | Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer | recruiting | Phase 2 | 86 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | recruiting | Phase 2 | 2,000 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT05583708 | Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer(iPRRT) | recruiting | Phase 2 | 18 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS) | active not recruiting | Phase 2 / Phase 3 | 760 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT05663866 | Premedication to Reduce Amivantamab Associated Infusion Related Reactions | active not recruiting | Phase 2 | 68 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT05715216 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05766891 | Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | recruiting | Phase 2 / Phase 3 | 225 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | active not recruiting | Phase 2 | 47 | Reid Merryman, MDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05877521 | Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief | active not recruiting | Phase 2 | 76 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05886491 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | TakedaINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT05907759 | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05908734 | A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer(PolyDamas) | active not recruiting | Phase 1 / Phase 2 | 71 | Janssen Research & Development, LLCINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05963074 | A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia(TAILOR) | active not recruiting | Phase 2 | 333 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06045247 | Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06052826 | Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study | recruiting | Phase 2 | 164 | City of Hope Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06106295 | Metyrapone for Mild Autonomous Cortisol Secretion (MACS) | active not recruiting | Phase 2 | 30 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 5 days agoSource updated unknownsource: clinicaltrials